Differentiated Therapy EndoStim offers an implantable neurostimulation therapy that addresses the root cause of GERD, providing an alternative for patients not adequately served by maximal PPI treatment and creating a compelling sales angle for gastroenterology and surgical centers treating drug refractory GERD.

Channel Partnerships With a lean team and a track record of pursuing commercialization, there is strong potential to scale via distribution partnerships, OEM collaborations, or co marketing with established medical device networks to reach hospitals and GI clinics quickly.

Reimbursement Pathways Advise prioritization of payer engagement and evidence generation to secure coverage for device therapy in GERD, including economic models and patient selection criteria to help hospitals justify adoption.

Leadership Momentum A proactive leadership team focused on strategic partnerships and go to market execution can accelerate adoption; align with the executive team on sales targets, clinical education, and key account development in GI and surgical settings.

Unmet Need The large GERD patient population with drug refractory cases seeks innovative options beyond PPIs, so target gastroenterologists, GI surgeons, and hospital-based centers with strong physician education and clinical data to drive early adoption.